• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Encouraging early efficacy data from monotherapy part of ModiFY Phase 1/2 clinical trial

by admin | Feb 21, 2023 | Latest News, Moditope

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell in-licenses Vaccitech technology to advance Modi-2 towards the clinic

by admin | Nov 7, 2022 | Latest News, Modi-2, Moditope, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

First patient dosed in the expansion phase of the monotherapy arms of ModiFY

by admin | Oct 31, 2022 | Latest News, Modi-1, Moditope, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

First patient dosed in Cohort 2 of the ModiFY Phase 1 clinical trial

by admin | Aug 16, 2022 | Latest News, Modi-1, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

First patient dosed in Modi-1 Phase 1 clinical trial

by admin | Jun 13, 2022 | Latest News, Modi-1, Moditope, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Modi-1 Phase 1/2 clinical trial open for recruitment

by admin | Apr 13, 2022 | Latest News, Modi-1, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy